Start Submission Become a Reviewer

Reading: Resistant Hypertension and Renal Nerve Denervation

Download

A- A+
Alt. Display

Review Articles

Resistant Hypertension and Renal Nerve Denervation

Authors:

Matthew G. Denker ,

University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, US
About Matthew G.
M.D.
X close

Debbie L. Cohen

University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, US
About Debbie L.
M.D.
X close

Abstract

Patients with resistant hypertension are a subgroup of the hypertensive population that are at even greater risk of cardiovascular outcomes. Therapeutic options for these patients are limited to antihypertensive medications. However, renal denervation (RDN) is a novel nonpharmacologic intervention that involves a catheter-based ablation of the sympathetic nerves within the renal artery wall. The procedure initially showed promise with remarkable blood pressure reductions until the pivotal SYMPLICITY HTN-3 trial failed to demonstrate superiority of RDN over control. This trial was notable for a substantial placebo effect and an attenuated response to RDN. These findings, which contradicted those of prior studies, have raised numerous questions, including whether adequate RDN occurred in those patients. Further research is planned to resolve some of these questions and to clarify the role of RDN in treating patients with resistant hypertension.

How to Cite: 1. Denker MG, Cohen DL. Resistant Hypertension and Renal Nerve Denervation. Methodist DeBakey Cardiovascular Journal. 2015;11(4):240-244. DOI: http://doi.org/10.14797/mdcj-11-4-240
2
Views
2
Downloads
Published on 01 Oct 2015.
Peer Reviewed

Downloads

  • PDF (EN)